Novavax Inc. ($NVAX) Stock Forecast: Up 6.4% Today

What is Novavax Inc.?

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company recognized for its vaccine technology, specifically its protein-based vaccine platform and Matrix-M adjuvant. The stock experienced a notable bullish trend in today's market.

Why is Novavax Inc. going up?

NVAX stock is up 6.4% on Feb 19, 2026 19:25

• Anticipation and positive investor sentiment toward Novavax's forthcoming financial results announcement on February 26, 2026, have fueled the bullish movement.
• Ongoing cost optimization, strategic alliances, and sustained demand for its COVID-19 vaccine have propelled Novavax's stock price upward, positioning it as an attractive investment opportunity.
• The favorable market conditions, along with a new partnership with Pfizer and growing interest in protein-based vaccines, have further accelerated Novavax's stock performance.
• Analysts' outlooks on Novavax's revenue and earnings prospects, as well as the potential for growth based on fair value assessments, have contributed to the market enthusiasm surrounding the stock's recent bullish trajectory.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Novavax, Inc. (Nasdaq: NVAX) has announced that it will report its fourth quarter and full year 2025 financial results and operational highlights on Thursday, February 26, 2026, at 8:30 a.m. ET. The company will host a conference call and webcast to discuss the results, with replay options available until early March 2026. Novavax, known for its vaccine technology, aims to maximize the impact of its Matrix-M adjuvant and R&D assets through strategic partnerships.

https://sg.finance.yahoo.com/news/novavax-report-fourth-quarter-full-130000606.html

Assessing Novavax (NVAX) Valuation After Recent Share Price Momentum And Partnership Shifts

Novavax (NVAX) has seen recent positive share price momentum, with gains over the past day, week, month, and three months, contrasting its significant five-year decline. The stock is currently trading at a substantial discount to analyst price targets and Simply Wall St's intrinsic value model. The prevailing narrative suggests NVAX is undervalued due to ongoing cost optimization, a shift to a partnership-focused model, and improved margins, though this depends on partner milestones and sustained COVID-19 vaccine demand.

https://uk.finance.yahoo.com/news/assessing-novavax-nvax-valuation-recent-070909692.html

Novavax (NVAX) Is Up 5.5% After Easing Inflation Boosts Interest In Protein-Based Vaccines

Novavax (NVAX) saw its stock rise by 5.5% following softer-than-expected U.S. inflation data, which reignited interest in its protein-based vaccine platform as an alternative to mRNA technologies. Despite investor optimism and a new licensing agreement with Pfizer, the company's investment narrative still hinges on its adjuvant platform generating recurring royalties and supply revenue from partners, rather than standalone product sales. Analysts' opinions on Novavax vary widely, with some forecasting significant revenue and earnings declines, while others project a 51% upside to its current price based on a fair value of $13.11.

https://www.sahmcapital.com/news/content/novavax-nvax-is-up-55-after-easing-inflation-boosts-interest-in-protein-based-vaccines-2026-02-14

Trending Today

PNC Financial Services Group Inc. (The) ($PNC) Stock Forecast: Down 5.2% Today

Western Digital Corporation ($WDC) Stock Forecast: Down 5.9% Today

Capital One Financial Corporation ($COF) Stock Forecast: Down 5.4% Today

Accenture plc Class A (Ireland) ($ACN) Stock Forecast: Down 5.5% Today

International Business Machines Corporation ($IBM) Stock Forecast: Down 7.6% Today

Ethereum ($ETH) Crypto Forecast: Down 5.8% Today

Bitcoin ($BTC) Crypto Forecast: Down 5.0% Today

XRP ($XRP) Crypto Forecast: Down 5.1% Today

ZCash ($ZEC) Crypto Forecast: Down 5.4% Today

Opendoor Technologies Inc. ($OPEN) Stock Forecast: Down 10.2% Today

Novavax Inc. Price History

05.01.2026 - NVAX Stock was down 5.1%

• Novavax's stock showed a decline compared to the general market performance today.
• The drop in NVAX's stock value may be linked to the upcoming earnings report, which is anticipated to reveal negative earnings per share (EPS) and revenue numbers for the quarter.
• Despite the approval from the FDA for Novavax's COVID-19 vaccine, the stock encountered selling pressure, possibly due to profit-taking or market sentiment.
• The recent reevaluation of NVAX to a "sell" rating by Wall Street Zen could have also contributed to the downward trend, highlighting worries about the company's financial position and worth.

30.00.2026 - NVAX Stock was down 5.3%

• Novavax's stock faced a downward trend despite the announcement of a licensing agreement with Pfizer for its Matrix-M adjuvant technology, which is viewed as a potential source of significant revenue.
• The decline in stock price may be linked to concerns regarding the company's core business in coronavirus vaccines, revenue inconsistencies, and challenges in internal vaccine development, as highlighted in recent discussions.
• There has been a notable increase in short interest and negative market sentiment towards Novavax, with a notably higher short interest compared to similar companies, potentially influencing the stock's downturn.
• Investors are awaiting Novavax's upcoming earnings report, anticipating a year-over-year decline in EPS and revenue, contributing to a cautious sentiment regarding the stock's future despite recent positive developments.

13.01.2026 - NVAX Stock was up 5.1%

• Novavax (NVAX) stock showed resilience today, increasing by 2.51% while major indices such as the S&P 500, Dow, and Nasdaq faced minor declines.
• Analysts hold a positive outlook on Novavax's upcoming financial performance, anticipating substantial growth in earnings and revenue, which is likely fueling the favorable market sentiment towards the stock.
• Investor interest in Novavax as a potential biotech success story, alongside its protein-based vaccine technology as an alternative to mRNA, has attracted capital despite the stock's inherent volatility and competition in the sector.
• Anticipated expansion in the Human Vaccine Adjuvants Market is also instilling confidence in Novavax's future potential, supported by ongoing advancements in vaccine technology and the global emphasis on personalized medicine driving industry growth.

12.01.2026 - NVAX Stock was down 5.9%

• Speculation regarding NVAX's potential resurgence in the biotech sector could have heightened stock volatility.
• Allianz Asset Management GmbH's notable increase in NVAX stake likely boosted investor confidence initially, though subsequent profit-taking actions may have contributed to the bearish trend.
• Despite exceeding revenue expectations, investors may have been deterred by mixed sentiment and concerns regarding the stock's high volatility and risks.
• Market-wide declines in key indices like the S&P 500, Dow, and Nasdaq may have exerted additional selling pressure on NVAX, impacting its performance despite positive company updates.

19.01.2026 - NVAX Stock was up 6.4%

• Anticipation and positive investor sentiment toward Novavax's forthcoming financial results announcement on February 26, 2026, have fueled the bullish movement.
• Ongoing cost optimization, strategic alliances, and sustained demand for its COVID-19 vaccine have propelled Novavax's stock price upward, positioning it as an attractive investment opportunity.
• The favorable market conditions, along with a new partnership with Pfizer and growing interest in protein-based vaccines, have further accelerated Novavax's stock performance.
• Analysts' outlooks on Novavax's revenue and earnings prospects, as well as the potential for growth based on fair value assessments, have contributed to the market enthusiasm surrounding the stock's recent bullish trajectory.

28.00.2026 - NVAX Stock was down 5.1%

• The bearish movement in NVAX stock today may be attributed to concerns about the company's lack of growth prospects despite the recent surge in share price.
• The licensing agreement with Pfizer, though positive for industry validation and potential revenue streams, may not have been enough to offset investor worries about the company's future growth.
• The underperformance of NVAX compared to the broader market gains could have also contributed to the downward pressure on the stock today.
• Overall, the market sentiment towards NVAX seems to be cautious due to uncertainties surrounding its growth trajectory and revenue forecasts, leading to the bearish movement observed today.

28.00.2026 - NVAX Stock was down 5.1%

• The decline in NVAX stock today might be due to profit-taking following a recent rise in share price, along with concerns about the company's revenue forecast and growth outlook.
• While the collaboration with Pfizer is a positive step, it may not have been sufficient to maintain positive momentum, especially as some analysts have raised alerts about execution risks and potential revenue declines.
• The significant increase in the purchasing of call options suggests short-term optimism, but overall sentiment appears cautious due to the company's modest growth prospects.
• Investors are eagerly anticipating Novavax's forthcoming financial results, which are expected to reveal a decrease in EPS and revenue for the quarter, potentially exerting further downward pressure on the stock.

22.00.2026 - NVAX Stock was up 9.1%

• The bullish movement in NVAX today can be attributed to the significant licensing agreement with Pfizer, which includes upfront payment, potential milestones, and royalties, boosting investor confidence and leading to a surge in the stock price.
• The high volume of call options being bought indicates short-term bullish sentiment among traders, further driving up the stock price.
• Despite the positive news and reiterated "Buy" ratings from analysts, there are concerns about execution risks and revenue declines, leading to a divided opinion among analysts and hedge funds.
• While NVAX presents a unique opportunity in the vaccine market, the stock's volatility and speculative nature suggest that it may be more suitable for traders seeking short-term gains rather than long-term stability.

23.00.2026 - NVAX Stock was down 5.1%

• The recent 46% surge in Novavax's stock price sparked concerns over the company's growth potential, with analysts foreseeing a substantial revenue decline in contrast to industry trends. This disparity is likely driving the prevailing bearish sentiment surrounding NVAX.
• Despite a favorable non-exclusive licensing agreement with Pfizer and a rise in call options indicating short-term bullish sentiment, fears related to execution risks and revenue decreases are tempering overall investor confidence in Novavax.
• The significant deal with Pfizer, which involved a sizeable upfront payment and potential milestones, was initially well-received, leading to a stock price increase. However, uncertainties surrounding Novavax's growth path and financial prospects may be overshadowing the immediate advantages of the collaboration.
• Analyst perspectives on NVAX are divided, with some firms maintaining a "Buy" rating while others adjusting price targets downwards. This diverse outlook, combined with worries about the company's valuation and revenue projections, could be contributing to today's bearish market activity.

03.01.2026 - NVAX Stock was down 5.0%

• The FDA approval of Novavax's COVID-19 vaccine raised expectations, but the stock saw a downward trend, possibly due to profit-taking.
• Despite securing a licensing agreement with Pfizer for its Matrix M adjuvant, Wall Street Zen's downgrade to a "sell" rating caused stock pressure amid concerns about financial performance.
• BofA's increased price target and positive options activity generated some optimism. However, uncertainties over asset development timing under the license tempered investor enthusiasm.
• Pfizer's strategic collaborations with Novavax and other developments may have indirectly influenced Novavax's stock movement as investors reevaluated the pharmaceutical industry landscape.

21.00.2026 - NVAX Stock was up 20.0%

• The rise in NVAX today is possibly linked to a new license agreement with Pfizer, indicating a temporary positive outlook among investors.
• Renewed support from BTIG, maintaining a "Buy" rating with a $19 price target, has bolstered confidence in NVAX's potential, despite differing analyst perspectives and adjustments from other companies.
• The CEO's focus on the success of the company's Matrix-M technology and growth strategy during the J.P. Morgan Healthcare Conference likely played a part in the favorable market movement, underscoring Novavax's standing in the global vaccine industry.
• Despite uncertainties regarding execution risks and revenue drops, the generally upbeat news related to NVAX's partnerships and vaccine technology appears to have eclipsed the cautious views, propelling the stock upwards.

10.01.2026 - NVAX Stock was up 6.6%

• Novavax stock showed bullish movement today, outperforming major market indices like the S&P 500, Dow, and Nasdaq.
• This positive trend is linked to Allianz Asset Management GmbH significantly increasing its stake in Novavax, Inc. by 162.6% in the third quarter, showcasing confidence in the company's future.
• The growth forecast for the Human Vaccine Adjuvants Market, where Novavax is a key player, likely boosted optimism around the stock.
• Despite facing challenges like negative free cash flow and revenue decline, analysts foresee a potential 48% upside for Novavax. It's vital to closely monitor strategic developments and regulatory milestones due to the speculative nature of this opportunity.